Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer
Tomoya Yokota,Tsuyoshi Onoe,Hirofumi Ogawa,Satoshi Hamauchi,Yoshiyuki Iida,Tomoyuki Kamijo,Toshihito Suda,Takashi Yurikusa,Tetsuo Nishimura,Hirofumi Yasui,Tetsuro Onitsuka +10 more
Reads0
Chats0
TLDR
Prophylactic percutaneous endoscopic gastrostomy is recommended because most patients receiving cetuximab and radiotherapy for locally advanced head and neck squamous cell carcinoma have Grade ≥ 3 mucositis with distinctive features.Abstract:
Objective Prophylactic percutaneous endoscopic gastrostomy may be considered before chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma, because severe mucositis is a common complication. We evaluated the mucosal findings and necessity of prophylactic percutaneous endoscopic gastrostomy in patients with head and neck squamous cell carcinoma receiving cetuximab and radiotherapy. Methods Fourteen consecutive patients with locally advanced head and neck squamous cell carcinoma receiving cetuximab and radiotherapy were analyzed. Results Patients' backgrounds were as follows: male/female, 8/6; median age, 64.5 years (range, 35-83 years); performance status, 0/1, 9/5. Primary tumor sites included the oropharynx, hypopharynx and larynx in four, seven and three patients, respectively. Patients completed a median of eight cetuximab cycles. All patients received three-dimensional conformal radiotherapy (median dose, 70 Gy). Thirteen patients were treated with elective neck irradiation at the ipsilateral (n = 3) or bilateral (n = 10) nodes. Grade ≥ 3 mucositis/stomatitis (clinical examination) occurred in 85.7% patients (n = 12). The median irradiation dose was 33 Gy at the Grade 3 mucositis onset. Eight patients showed mucositis with distinctive features, a wide range of white-coated lesions with a clear border; hypopharyngeal atresia was observed in two patients. Prophylactic percutaneous endoscopic gastrostomy was performed in 11 patients, and 11 patients (78.6%) actually required nutritional support because of Grade ≥ 3 mucositis/stomatitis (functional/symptomatic). Conclusions Prophylactic percutaneous endoscopic gastrostomy is recommended because most patients receiving cetuximab and radiotherapy for locally advanced head and neck squamous cell carcinoma have Grade ≥ 3 mucositis with distinctive features.read more
Citations
More filters
Journal ArticleDOI
Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients.
Marie Kurokawa,Miho Watanabe Nemoto,Rintaro Harada,Hiroki Kobayashi,Takuro Horikoshi,A. Kanazawa,G. Togasaki,Yukinao Abe,Hideaki Chazono,Toyoyuki Hanazawa,Yoshitaka Okamoto,Takashi Uno +11 more
TL;DR: BRT using cetuximab for Japanese patients with SCCHN was feasible as an alternative for cisplatin-based concurrent chemoradiation, although longer follow-up is necessary to evaluate late toxicities.
DissertationDOI
Optimising nutrition support in patients with head and neck cancer
TL;DR: This thesis aims to demonstrate the efforts towards in-situ applicability of EMMARM, as to provide real-time information about concrete mechanical properties such as E-modulus and compressive strength.
Journal ArticleDOI
How Should We Approach Locally Advanced Squamous Cell Carcinoma of Head and Neck Cancer Patients Ineligible for Standard Non-surgical Treatment?
Tomoya Yokota,Satoshi Hamauchi,H. Shirasu,Yusuke Onozawa,Hirofumi Ogawa,Tsuyoshi Onoe,Tetsuro Onitsuka +6 more
TL;DR: A review of therapeutic alternatives to high-dose cisplatin-based treatment in the setting of definitive and postoperative chemoradiotherapy (CRT) or induction chemotherapy in patients ineligible for the standard of care is provided.
Journal ArticleDOI
Artificial nutrition dependence after cetuximab versus cisplatin combined with radiotherapy for advanced head and neck cancer: A propensity score-matched analysis.
TL;DR: The purpose of this study was to compare the effect of cetuximab‐based radiotherapy with cisplatin‐based concomitant chemoradiotherapy (CCRT) on artificial nutrition dependence in locoregional advanced head and neck cancer.
Journal ArticleDOI
Prophylactic management of radiation-induced mucositis using herbal mouthwash in patients with head and neck cancer: an assessor-blinded randomized controlled trial
Sirikorn Kongwattanakul,Nutjaree Petchann,Petcharat Petroch,Saengrawee Thanthong,Sunanta Tungfung,Sasikarn Chamchod,Supaporn Pitiporn,Danupon Nantajit +7 more
TL;DR: Herbal mouthwashes with payayor and fingerroot were tested their efficacies in preventing and reducing severity of RIOM in comparison with normal saline with sodium bicarbonate and proved similarly effective in prophylaxis.
References
More filters
Journal ArticleDOI
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
James A. Bonner,Paul M. Harari,Jordi Giralt,Nozar Azarnia,Dong M. Shin,Roger B. Cohen,Christopher U. Jones,Ranjan Sur,David Raben,Jacek Jassem,Roger Ove,Merrill S. Kies,José Baselga,Hagop Youssoufian,Nadia Amellal,Eric K. Rowinsky,Eric K. Rowinsky,K. Kian Ang +17 more
TL;DR: Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoreGional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head andneck.
Journal ArticleDOI
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer
Arlene A. Forastiere,Helmuth Goepfert,Moshe H. Maor,Thomas F. Pajak,Randal S. Weber,William H. Morrison,Bonnie S. Glisson,Andy Trotti,John A. Ridge,C. Chao,Glen Peters,Ding Jen Lee,Andrea Leaf,John F. Ensley,Jay S. Cooper +14 more
TL;DR: In patients with laryngeal cancer, radiotherapy with concurrent administration of cisplatin is superior to induction chemotherapy followed by radiotherapy or radiotherapy alone for larynGEal preservation and locoregional control.
Journal ArticleDOI
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
James A. Bonner,Paul M. Harari,Jordi Giralt,Roger B. Cohen,Christopher U. Jones,Ranjan Sur,David Raben,José Baselga,Sharon A. Spencer,Junming Zhu,Hagop Youssoufian,Eric K. Rowinsky,K. Kian Ang +12 more
TL;DR: Overall survival was significantly improved in those who experienced an acneiform rash of at least grade 2 severity compared with patients with no rash or grade 1 rash, confirming cetuximab plus radiotherapy as an important treatment option in this group of patients.
Journal ArticleDOI
Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis
Mitchell Machtay,Jennifer Moughan,Andrew Trotti,Adam S. Garden,Randal S. Weber,Jay S. Cooper,Arlene A. Forastiere,K. Kian Ang +7 more
TL;DR: Older age, advanced T-stage, and larynx/hypopharynx primary site were strong independent risk factors and neck dissection after CCRT was associated with an increased risk of these complications.
Journal ArticleDOI
Head and neck cancer: changing epidemiology, diagnosis, and treatment.
TL;DR: This review focuses on the goal of organ preservation and postoperative treatment of high-risk patients with the concurrent use of chemotherapy and radiation therapy with the role of inhibitors of the epidermal growth factor receptor in locally advanced and recurrent/metastatic squamous cell cancer of the head and neck.